

Summary of Financial Results
for the First Quarter of Fiscal Year Ending December 31, 2018
[Japanese GAAP] (Non-consolidated)

May 10, 2018

Company Name	Symbio Pharmaceuticals Limited	Listing: Tokyo Stock Exchange
Securities Code	4582	URL: http://www.symbiopharma.com/
Representative	Representative Director, President and Chief Executive Officer	Fuminori Yoshida
Contact Person	Corporate Officer, Director of Finance & Accounting and Chief Financial Officer	Kenji Murata TEL +81-3-5472-1125
Scheduled Date to File Quarterly Report	May 11, 2018	Date of Dividend Payment (plan) —

Supplementary materials for quarterly financial results: Yes No

Holding of quarterly earnings performance review: Yes No

(Millions of yen – rounded down, unless otherwise stated)

1. Business Results for the First Quarter of FY 2018 (cumulative) (January 1, 2018 to March 31, 2018)

(1) Operating Results (cumulative)

(Percentages indicate year-on-year changes)

	Net Sales		Operating Income (Loss)		Ordinary Income (Loss)		Quarterly Net Income (Loss)	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
1Q FY 2018	888	2.1	(714)	—	(748)	—	(759)	—
1Q FY 2017	869	350.1	(525)	—	(583)	—	(582)	—

	Quarterly Net Income (Loss) per Share	Diluted Quarterly Net Income per Share
	Yen	Yen
1Q FY 2018	(13.28)	—
1Q FY 2017	(12.12)	—

(Note) Diluted quarterly net income per share is not stated above due to quarterly net loss per share, despite the potential dilution of shares.

(2) Financial Position

	Total Assets	Net Assets	Equity Ratio
	Millions of yen	Millions of yen	%
1Q FY 2018 (as of March 31, 2018)	4,216	3,327	65.7
FY 2017 (as of December 31, 2017)	4,252	3,239	63.6

(Reference) Shareholders' equity: 1Q FY 2018 (as of March 31, 2018) 2,769 million yen
 FY 2017 (as of December 31, 2017) 2,702 million yen

2. Dividends

	Annual Dividend per Share				
	1st Quarter	2nd Quarter	3rd Quarter	Fiscal Year End	Full Year
	Yen	Yen	Yen	Yen	Yen
FY 2017	—	0.00	—	0.00	0.00
FY 2018	—				
FY 2018 (Forecast)		0.00	—	0.00	0.00

(Note) Revision of dividend forecasts recently announced: Yes No

3. Earnings Forecasts for FY 2018 (January 1, 2018 to December 31, 2018)

(Percentages indicate year-on-year changes)

Full Year	Net Sales		Operating Income (Loss)		Ordinary Income (Loss)		Net Income (Loss)		Net Income (Loss) per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
	4,201	22.0	(2,981)	—	(3,044)	—	(3,056)	—	(52.99)

(Note) Revision of earnings forecasts recently announced: Yes · No

Notes:

(1) Application of special accounting treatment in preparation of quarterly financial reports: Yes · No

(2) Changes in accounting policies, changes in accounting estimates and restatements after error corrections

(a) Changes in accounting policies due to revision of accounting standards: Yes · No

(b) Changes in accounting policies due to other reasons: Yes · No

(c) Changes in accounting estimates: Yes · No

(d) Restatements after error corrections: Yes · No

(3) Number of shares outstanding (common stock)

(i) Number of shares outstanding at the end of the period (including treasury stock)	1Q FY 2018	57,828,524 shares	FY 2017	54,049,224 shares
(ii) Number of shares of treasury stock at the end of the period	1Q FY 2018	75 shares	FY 2017	75 shares
(iii) Average number of shares during the period (cumulative)	1Q FY 2018	57,221,360 shares	1Q FY 2017	48,095,755 shares

* The quarterly financial statements are not subject to quarterly reviews by certified public accountants or an accounting auditor.

* Explanation regarding the appropriate use of earnings forecasts and other matters

All forecasts presented in this document, including the earnings outlook, are based on the information currently available to management and assumptions determined by management to be reasonable. Actual results may differ substantially from these forecasts due to various factors. Regarding the assumptions on which the Company's earnings forecasts are based and their usage, please refer to "1. Qualitative Information Concerning Quarterly Financial Results, (3) Qualitative information concerning earnings forecasts," on page 3 of the attachment.

Index of the attachment

1. Qualitative Information Concerning Quarterly Financial Results	1
(1) Qualitative information concerning business results	1
(2) Qualitative information concerning financial position	3
(3) Qualitative information concerning earnings forecasts	3
2. Quarterly Financial Statements and Primary Notes	4
(1) Quarterly balance sheets	4
(2) Quarterly statements of operations (cumulative)	5
(3) Notes on quarterly financial statements	6
(Notes regarding going concern assumption)	6
(Notes regarding significant changes in shareholders' equity)	6
(Significant subsequent events)	6

1. Qualitative Information Concerning Quarterly Financial Results

(1) Qualitative information concerning business results

Progress in the Company's business for the first quarter of FY 2018 is as follows:

(i) Domestic

[Anticancer agent: SyB L-0501 (lyophilized powder formulation), SyB L-1701 (ready-to-dilute ("RTD") formulation), SyB L-1702 (rapid infusion ("RI") formulation) and SyB C-0501 (oral formulation) (generic name: bendamustine hydrochloride, trade name: TREAKISYM®)]

The Company markets TREAKISYM® in Japan through its business partner, Eisai Co., Ltd. ("Eisai"). The Company obtained marketing approval for first-line treatment of low-grade non-Hodgkin's lymphoma and mantle cell lymphoma in December 2016, and for chronic lymphocytic leukemia in August 2016. These are in addition to the approvals for the indications of recurrent/refractory low-grade non-Hodgkin's lymphoma and mantle cell lymphoma which were obtained in October 2010. Following this indication expansion, TREAKISYM® is steadily increasing its market share in the area of first-line treatment by replacing R-CHOP, the conventional standard treatment, resulting in a significant in-market sales increase of 32.4% year-on-year (NHI price basis). Net sales to Eisai progressed as planned.

In addition to the three already-approved indications, the Company has started a Phase III clinical trial for recurrent/refractory intermediate/high-grade non-Hodgkin's lymphoma (diffuse large B-cell lymphoma, or "DLBCL") and is currently working on patient enrollment towards obtaining approval. The trial is in response to serious need at clinics and hospitals as there is currently no reliable standard treatment. Patient groups have petitioned to the regulatory authorities for the approval of BR therapy. With a view to providing new therapeutic alternatives and to maximize product value, the Company engaged in consultations with the Pharmaceuticals and Medical Devices Agency ("PMDA") after the completion of a Phase II clinical trial. The Company began the Phase III clinical trial in August 2017 and the first patient was enrolled in January 2018.

In addition to these initiatives toward the approval of additional indications, the Company entered into an exclusive license agreement with Eagle Pharmaceuticals, Inc. (head office: New Jersey, U.S.) ("Eagle") in September 2017, under which Eagle licensed to the Company rights under Eagle's intellectual property to develop, market, and sell Eagle's RTD and RI liquid formulations (TREAKISYM® liquid formulation)^(Note 1) in Japan. This will further enable the Company to extend the product life until 2031 through patent protection and maximize the value of TREAKISYM®, while bringing significant benefits to patients and healthcare providers. The Company is in the process of preparing for the application for the approval of the RTD formulation and for a clinical trial for the RI formulation, following consultations with the PMDA.

In addition to the development and expansion of the intravenous formulation product, the Company is exploring the development of an oral formulation of TREAKISYM® with a focus on the treatment of solid tumors and autoimmune diseases and intends to further expand the business, with an aim to solidify its business through a platform of TREAKISYM® products. Amid such initiatives, the Company commenced a Phase I clinical trial for progressive solid tumors in January 2018, with the aim of examining the recommended dosage and schedule as well as tolerability and safety of the oral formulation of TREAKISYM®, and identifying potential target tumor types. Meanwhile, with a view to evaluating the effect of oral administration of TREAKISYM® on the immune system, the Company concluded a joint research agreement with Keio University in May 2018 to conduct a pre-clinical trial to verify the therapeutic value of this product in the treatment of systemic lupus erythematosus (SLE), a form of autoimmune disease.

(Note 1) RTD and RI are pre-dissolved liquid formulations that differ from the currently available freeze-dried ("FD") powder formulation. RTD (ready-to-dilute) will significantly reduce the preparation time and labor cost for healthcare providers, and RI (rapid infusion) will reduce infusion duration to 10 minutes from the current 60 minutes, providing significant benefit and value to both patients and healthcare providers.

[Anticancer agents: SyB L-1101 (intravenous formulation) and SyB C-1101 (oral formulation), generic name: rigosertib sodium]

U.S. Licensor Onconova Therapeutics, Inc. (head office: Pennsylvania, U.S.) ("Onconova") is conducting a global Phase III clinical trial (with trial sites in more than 20 countries) of the intravenous formulation of rigosertib for higher-risk myelodysplastic syndromes (HR-MDS) which do not respond to the current standard treatment with hypomethylating agents ("primary HMA failure") or which relapse after treatment under the current standard of care. The Company is responsible for clinical development in Japan and in December 2015 began a domestic trial. More than 30 patients are already enrolled and patient enrollment is proceeding favorably. Based on the results of the interim analysis completed in

January 2018, the Company will continue the trial with a one-time increase in patient enrollment in accordance with pre-determined statistical criteria. On the basis of these results, the Company is planning to apply for approval in Japan at the same time as in the U.S. and Europe.

As for the oral formulation of rigosertib, Onconova has been conducting Phase I/II clinical trials in the U.S. for the target indication of first-line higher-risk myelodysplastic syndromes (MDS) (in combination with azacitidine^(Note 2)), along with a Phase II clinical trial for the target indication of transfusion-dependent lower-risk MDS. The Company started a domestic Phase I clinical trial in June 2017 to confirm the tolerability and safety of the oral formulation of rigosertib for Japanese patients. The first patient was enrolled in October 2017 and patient enrollment is proceeding favorably. After completion of this trial, the Company plans to conduct a clinical trial for combination therapy with azacitidine, to take part in Onconova's planned global Phase III clinical trial for combination therapy with azacitidine for the first-line treatment of patients with higher-risk MDS, and to apply for approval of the oral formulation of rigosertib in Japan in timing alignment with the U.S. and Europe. With respect to the development for the target indication of transfusion-dependent lower-risk MDS, the Company will continue to monitor Onconova's development activities with a view to participating from Japan.

(Note 2) About azacitidine (Vidaza[®]; currently marketed by Nippon Shinyaku Co., Ltd.): This drug (for injection) was approved in 2011 based on results showing extended overall survival for the first time in the Phase III clinical trial for the indication of MDS. It is currently used as a first-line drug for MDS patients who have difficulties in hematopoietic stem cell transplantation. MDS is a preleukemic state, and decrease in tumor suppressor gene due to excessive methylation of DNA is thought to be related to the disease. Hypomethylating agents such as azacitidine are thought to suppress progress to leukemia by restoring tumor suppressor gene with a deterrent effect against methylation of DNA.

[Patient-controlled iontophoretic transdermal system for the short-term management of acute post-operative pain: SyB P-1501]

In October 2015, the Company entered into an agreement with Incline Therapeutics, Inc., a wholly-owned subsidiary of US-based The Medicines Company (Head Office: New Jersey, U.S.) for an exclusive license to develop and commercialize SyB P-1501 in Japan. The Company, acting in the best interest of patients, determined to temporarily suspend new patient enrollment for SyB P-1501 from April 21, 2017 due to its recently arising concern as to the continuity of The Medicines Company's business regarding the product.

The Company later initiated arbitration against The Medicines Company on October 11, 2017 under the rules of the International Chamber of Commerce, seeking damages of 82 million U.S. dollar (approximately 9.0 billion yen) arising from The Medicines Company's repudiation of the license agreement. The Company claims that The Medicines Company failed to provide the Company with adequate assurance of performance of its contractual obligations under the license agreement in light of its decision to discontinue commercialization activities regarding the product and withdraw from markets in the U.S. and Europe, and that such failure by The Medicines Company is a material breach of the license agreement. Furthermore, the Company terminated the license agreement on November 30, 2017, based on the fact that breach of the license agreement by The Medicines Company was not remedied within the stipulated time, and terminated the development of SyB P-1501 on February 9, 2018.

[New drug candidates]

The Company continues to actively seek new drug candidates and in-licensing opportunities globally, aiming to expand both profitability and growth potential over the medium-to-long-term, and discussions with multiple potential licensors are ongoing.

In May 2016, the Company established a wholly-owned subsidiary, Symbio Pharma USA, Inc. (Menlo Park, California, U.S., "Symbio Pharma USA"), as the Company's planned strategic base for overseas business development. Acquiring rights to new drug candidates through Symbio Pharma USA as the base of global business will be part of the Company's continued transformation into a global specialty biopharmaceutical company with capability to develop and commercialize new drugs in the U.S., Japan, Europe, and other major global markets.

(ii) Markets outside Japan

SyB L-0501 is also marketed in South Korea, Taiwan and Singapore and the product sales of SyB L-0501 in these countries progressed mainly in line with the Company's forecasts.

(iii) Business results (cumulative)

As a result of the above, net sales totaled 888,229 thousand yen for the first quarter of fiscal year ending December 31, 2018, primarily reflecting product sales of TREAKISYM®. Overall net sales rose 2.1% year-on-year.

Selling, general and administrative expenses totaled 964,024 thousand yen (a year-on-year increase of 26.1%), including research and development (“R&D”) expenses of 416,247 thousand yen (a year-on-year increase of 5.3%) primarily due to expenses associated with the clinical trial for the intravenous and oral formulations of TREAKISYM® as well as the intravenous and oral formulations of rigosertib, and other selling, general and administrative expenses of 547,777 thousand yen (a year-on-year increase of 48.4%).

As a result, an operating loss of 714,524 thousand yen was recognized for the first quarter of fiscal year ending December 31, 2018 (compared to an operating loss of 525,204 thousand yen for the first quarter of the previous fiscal year). In addition, including non-operating expenses totaling 34,964 thousand yen primarily comprised of foreign exchange losses, ordinary loss totaled 748,913 thousand yen (compared to an ordinary loss of 583,008 thousand yen for the first quarter of the previous fiscal year) and net loss totaled 759,692 thousand yen (compared to a net loss of 582,768 thousand yen for the first quarter of the previous fiscal year).

Segment information has been omitted as the Company operates within a single segment of the pharmaceutical industry, which includes the development and commercialization of drugs, manufacturing, marketing and other related activities.

(2) Qualitative information concerning financial position

Total assets as of March 31, 2018 stood at 4,216,150 thousand yen, a decrease of 36,134 thousand yen from the previous fiscal year end. The decrease was primarily due to decreases of 160,274 thousand yen in merchandise and finished goods, 80,093 thousand yen in consumption taxes receivable and 13,918 thousand yen in lease and guarantee deposits, offsetting increases of 186,997 thousand yen in cash and deposits, 18,160 thousand yen in advances paid and 10,729 thousand yen in buildings.

Liabilities stood at 888,465 thousand yen, a decrease of 124,416 thousand yen from the previous fiscal year end, primarily reflecting a decrease of 219,083 thousand yen in accounts payable-trade and 30,427 thousand yen in income taxes payable, offsetting an increase of 120,881 thousand yen in accounts payable-other.

Net assets increased by 88,282 thousand yen from the previous fiscal year end to 3,327,684 thousand yen, due to the exercise of stock acquisition rights, etc., offsetting a decrease of 759,692 thousand yen in retained earnings following the recognition of net loss.

As a result, the equity ratio increased to 65.7% by 2.1 percentage points from the previous fiscal year end.

(3) Qualitative information concerning earnings forecasts

No revision was made to the earnings forecasts for FY 2018 as of the date of this document.

2. Quarterly Financial Statements and Primary Notes

(1) Quarterly balance sheets

(Unit: thousands of yen)

	FY 2017 (as of December 31, 2017)	1Q FY 2018 (as of March 31, 2018)
Assets		
Current assets		
Cash and deposits	2,947,059	3,134,057
Accounts receivable-trade	489,874	491,942
Merchandise and finished goods	362,514	202,240
Prepaid expenses	73,720	82,474
Advances paid	18,760	36,921
Consumption taxes receivable	98,440	18,347
Other	46,152	28,672
Total current assets	4,036,522	3,994,654
Non-current assets		
Property, plant and equipment		
Buildings, net	28,486	39,215
Tools, furniture and fixtures, net	18,322	20,100
Construction in progress	64	8,893
Total property, plant and equipment	46,873	68,209
Intangible assets		
Software	65,583	63,154
Software in progress	3,295	—
Total intangible assets	68,878	63,154
Investments and other assets		
Shares of subsidiaries	0	0
Long-term prepaid expenses	14,209	18,250
Lease and guarantee deposits	85,799	71,880
Total investments and other assets	100,008	90,131
Total non-current assets	215,761	221,495
Total assets	4,252,284	4,216,150
Liabilities		
Current liabilities		
Accounts payable-trade	604,382	385,298
Accounts payable-other	330,867	451,748
Income taxes payable	54,813	24,386
Other	21,427	25,587
Total current liabilities	1,011,490	887,021
Non-current liabilities		
Provision for retirement benefits	1,392	1,444
Total non-current liabilities	1,392	1,444
Total liabilities	1,012,882	888,465
Net assets		
Shareholders' equity		
Common stock	10,761,676	11,175,022
Capital surplus	10,731,676	11,145,022
Retained earnings (accumulated deficits)	(18,790,705)	(19,550,398)
Treasury stock	(17)	(17)
Total shareholders' equity	2,702,629	2,769,629
Stock acquisition rights	536,772	558,055
Total net assets	3,239,402	3,327,684
Total liabilities and net assets	4,252,284	4,216,150

(2) Quarterly statements of operations (cumulative)
(For the first quarter of the fiscal year ending December 31, 2018)

(Unit: thousands of yen)

	IQ FY 2017 (from January 1, 2017 to March 31, 2017)	IQ FY 2018 (from January 1, 2018 to March 31, 2018)
Net sales	869,614	888,229
Cost of goods sold	630,602	638,729
Gross profit	239,012	249,500
Selling, general and administrative expenses	764,216	964,024
Operating loss	(525,204)	(714,524)
Non-operating income		
Interest income	1,552	405
Interest on refund	69	116
Other	0	54
Total non-operating income	1,621	575
Non-operating expenses		
Commission fees	2,260	2,736
Stock issuance costs	1,969	5,012
Foreign exchange losses	55,197	27,215
Total non-operating expenses	59,426	34,964
Ordinary loss	(583,008)	(748,913)
Extraordinary gain		
Gain on reversal of stock acquisition rights	1,190	—
Total extraordinary gain	1,190	—
Extraordinary loss		
Loss on retirement of non-current assets	—	9,829
Total extraordinary loss	—	9,829
Loss before income taxes	(581,818)	(758,742)
Income taxes-current	950	950
Total income taxes	950	950
Net loss	(582,768)	(759,692)

- (3) Notes on quarterly financial statements
 (Notes regarding going concern assumption)
 None to be reported.

(Notes regarding significant changes in shareholders' equity)

During the first quarter of fiscal year ending December 31, 2018, new shares were issued upon the exercise of part of the 33rd and 42nd stock acquisition rights. As a result, during the first quarter of fiscal year ending December 31, 2018, common stock and capital surplus increased by 413,346 thousand yen and 413,346 thousand yen respectively, amounting to 11,175,022 thousand yen and 11,145,022 thousand yen respectively as of March 31, 2018.

(Significant subsequent events)

1. Issuance of 43rd stock acquisition rights (stock option)

At the Board of Directors' meeting held on March 29, 2018, a resolution was passed regarding the issuance of stock acquisition rights as stock option to the six (6) Directors of the Company as follows. The stock option was allotted to the relevant Directors on the allotment date of April 26, 2018.

Number of stock option	3,050 units
Class and number of shares underlying the stock option	Common stock 305,000 shares
Issue price/ Total issue price of the stock option	Issue price 19,800 yen Total issue price 60,390,000 yen
Amount to be paid in for the stock option	Amount to be paid in: 198 yen per share The recipient ("Recipient") shall set off his/her claims for compensation against the Company in lieu of payment of monies for the stock acquisition rights allotted.
Exercise price of the stock option	Exercise price per share of one (1) yen
Period during which the stock option can be exercised	From March 30, 2021 to March 29, 2028
Terms and conditions for exercise of the stock option	(1) The Recipient must have the status as a director or employee of the Company or its affiliates at the time of exercise. However, this is not necessarily the case if: (a) the Recipient is a director of the Company or its affiliates and retires due to the expiry of her/his term, (b) the Recipient is an employee of the Company or its affiliates and retires due to compulsory retirement or (c) the Recipient is a director or employee of the Company or its affiliates and the Board of Directors resolves that he/she has resigned or retired with honorable recognition. (2) For other terms and conditions, the Company and directors shall comply with the Stock Option Allotment Agreement concluded between the parties.
Increase in paid-in capital due to the issuance of shares upon exercise of the stock option	Increase in the amount of paid-in capital due to the issuance of shares upon the exercise of stock option shall be one-half of the maximum amount of paid-in capital increase and others, which is calculated in accordance with Article 17 of the Corporation Accounting Rules, and any fraction less than one (1) yen arising therefrom shall be rounded up to the nearest one (1) yen.
Matters concerning transfer of the stock option	Requires approval at the Board of Directors' meeting.

2. Issuance of 44th stock acquisition rights (stock option)

At the Board of Directors' meeting held on March 29, 2018, a resolution was passed regarding the issuance of stock acquisition rights as stock option to the 71 Company employees as follows. The stock option was allotted to relevant employees on the allotment date of April 26, 2018.

Number of stock option	4,648 units
Class and number of shares underlying the stock option	Common stock 464,800 shares
Issue price/ Total issue price of the stock option	Issue price 19,800 yen Total issue price 92,030,400 yen
Amount to be paid in for the stock option	Amount to be paid in: 198 yen per share The Recipient shall set off his/her claims for compensation against the Company in lieu of payment of monies for the stock acquisition rights allotted.
Exercise price of the stock option	Exercise price per share of one (1) yen
Period during which the stock option can be exercised	From March 30, 2021 to March 29, 2028
Terms and conditions for exercise of the stock option	(1) The Recipient must have the status as a director or employee of the Company or its affiliates at the time of exercise. However, this is not necessarily the case if: (a) the Recipient is a director of the Company or its affiliates and retires due to the expiry of her/his term, (b) the Recipient is an employee of the Company or its affiliates and retires due to compulsory retirement or (c) the Recipient is a director or employee of the Company or its affiliates and the Board of Directors resolves that he/she has resigned or retired with honorable recognition. (2) For other terms and conditions, the Company and the employees shall comply with the Stock Option Allotment Agreement concluded between the parties.
Increase in paid-in capital due to the issuance of shares upon exercise of the stock option	Increase in the amount of paid-in capital due to the issuance of shares upon the exercise of stock option shall be one-half of the maximum amount of paid-in capital increase and others, which is calculated in accordance with Article 17 of the Corporation Accounting Rules, and any fraction less than one (1) yen arising therefrom shall be rounded up to the nearest one (1) yen.
Matters concerning transfer of the stock option	Requires approval at the Board of Directors' meeting.

3. Issuance of 45th through 47th stock acquisition rights with exercise price revision clauses

The Company made a resolution at the Board of Directors' meeting held on April 9, 2018 to issue the 45th through 47th stock acquisition rights with exercise price revision clauses ("Stock Acquisition Rights"), for which payments were completed on April 25, 2018. The details are as follows.

Date of allotment	April 25, 2018
Total number of stock acquisition rights	50,000,000 units 45th Stock Acquisition Rights: 20,000,000 units 46th Stock Acquisition Rights: 15,000,000 units 47th Stock Acquisition Rights: 15,000,000 units
Issue price	¥23,100,000 in aggregate 45th Stock Acquisition Rights: ¥0.54 per unit 46th Stock Acquisition Rights: ¥0.44 per unit 47th Stock Acquisition Rights: ¥0.38 per unit
Number of underlying shares with respect to the stock acquisition rights issued	50,000,000 shares (one share per stock acquisition right)
Amount of funding	¥10,413,100,000 (Note)
Exercise price and conditions for revising the exercise price	<p>Initial exercise price 45th Stock Acquisition Rights: ¥207 46th Stock Acquisition Rights: ¥209 47th Stock Acquisition Rights: ¥211</p> <p>The exercise price of the Stock Acquisition Rights shall be initially revised on April 27, 2018, with revisions occurring each time that five price calculation dates (defined below) have passed. Price calculation dates are days on which trading sessions take place (hereinafter, "Trading Days") on the Tokyo Stock Exchange, Inc. (hereinafter, the "Tokyo Stock Exchange") and are days on which market-disrupting events (defined below) do not occur. In the event the exercise price is revised on the basis of this paragraph, on the next Trading Day following the fifth price calculation date counted from the date on which the exercise price was previously revised (including that date; hereinafter, the "Revision Date"), the exercise price shall be revised to an amount obtained by multiplying the simple average value of the volume weighted average price of SymBio's common shares in regular trading announced by the Tokyo Stock Exchange on each price calculation date of the five consecutive price calculation dates prior to the Revision Date (hereinafter, the "Price Calculation Period") using the exercise price revision ratios defined below, truncating fractional amounts less than one yen (hereinafter, the "Standard Exercise Price"). However, the price is revised to the minimum exercise price (described in the provisions of Paragraph 10 of the terms and conditions for the issuance of the Stock Acquisition Rights) if the Standard Exercise Price falls below the minimum exercise price.</p> <p>Exercise price revision ratios: 45th Stock Acquisition Rights: 92% 46th Stock Acquisition Rights: 93% 47th Stock Acquisition Rights: 94%</p> <p>In addition, in the event of a reason for adjustment based on the provisions of Paragraph 11 of the terms and conditions for the issuance of the Stock Acquisition Rights during one of the Price Calculation Periods, the volume weighted average price of SymBio's common shares in regular trading announced by the Tokyo Stock Exchange for each of the price calculation dates of that Price Calculation Period shall be adjusted, taking that reason into consideration.</p> <p>Market-disrupting events shall be defined as the occurrence of situations indicated below in relation to SymBio's common shares: (1) If SymBio's common shares are designated by the Tokyo Stock Exchange as a stock under supervision or a stock to be delisted;</p>

	<p>(2) If no regular trading of SymBio's common shares occurs on the Tokyo Stock Exchange during an entire day (if no trades are executed on the Tokyo Stock Exchange); and/or</p> <p>(3) If the nominal price of SymBio's common shares in regular trading ends below the minimum daily trading limit designated by the Tokyo Stock Exchange (maximum allowable single-day loss), (regardless of whether regular trading of SymBio's common shares on the Tokyo Stock Exchange is conducted through proportional allotment (stop distribution)).</p>
Method for subscription or allotment (Allottee)	All of the Stock Acquisition Rights shall be allotted to EVO FUND by third-party allotment.
Period during which the stock option can be exercised	From April 26, 2018 to April 26, 2021
Use of the funds	<p>(1) Development of in-licensed drugs</p> <p>(2) Creation of an independent sales structure</p> <p>(3) Investment in new in-licensing, M&A, and other means</p>

(Note) The total amount paid upon the exercise of the Warrants assumes the exercise of all stock acquisition rights at the initial exercise price. The amount of funds actually raised may vary, depending on the market environment at the exercise timing of the Warrants.